AOD-9604 for Health & Longevity

Created on 10/30/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

AOD-9604, a lab-made fragment of human growth hormone, is promoted for fat loss and joint cartilage repair. Human evidence leans against fat loss: the developer's larger study showed no clear weight loss, and today's daily injection is untested in people. In company studies of the oral form, side effects matched placebo except at the highest dose; the main risks stem less from the molecule than from how it is obtained. (Full Review)

Protocol

Oral trial regimen
0.25, 0.5 or 1 mg once daily
Oral tablets for 24 weeks in sponsor trials; 1–30 mg capsules for 12 weeks
Subcutaneous regimen
About 300 µg once daily, fasted
Anecdotal gray-market figure; forums report 250–500 µg daily in 2–3 injections; neither is trial-tested
Joint-focused regimen
0.25 mg weekly
Only tested joint dose, in rabbit knees; protocols combine it with hyaluronic acid or platelet-rich plasma
Time to effect
Weight loss (oral trials)
12 and 24 weeks
Trial assessment points; only the 12-week trial reported weight loss
Injected use
Unknown
No human data show when, or whether, an effect appears
Non-response
12 weeks
Course without measurable fat loss; matches the trials' first assessment point

Benefits

Contraindications
  • Competitive athletes subject to anti-doping testing
  • Pregnancy and breastfeeding
  • Active cancer or recent cancer history
  • Children and adolescents
  • Immunocompromised people using unverified injectables
Key Interactions
Theoretical (inferred from mechanism)
  • Growth hormone and its secretagogues (e.g., somatropin, CJC-1295)
  • Beta-blockers (e.g., propranolol, metoprolol)
  • GLP-1 receptor agonists (e.g., semaglutide, tirzepatide)
  • Over-the-counter sympathomimetics (e.g., pseudoephedrine) and caffeine
  • Lipolytic supplements (synephrine, yohimbine, green tea extract)
  • Intra-articular hyaluronic acid

Risk & Side Effects

  • High:
  • Medium:
  • Low: Headache, gastrointestinal upset and infusion-related euphoria; growth-hormone-like effects on glucose and IGF-1; cancer diagnoses; product identity, purity and sterility; serious adverse events reported to FDA
  • Speculative: Immune reactions to injected products

Monitoring

Marker Target Why
Body weight and waist circumference No established target; track change from own baseline Fat loss is the claimed effect
Body fat mass (DEXA) No established target; track change from own baseline Distinguishes fat loss from lean-mass loss
Fasting glucose 70–99 mg/dL Safety check; a sustained rise prompts stopping
HbA1c 4.0–5.6% Safety check; average glucose over about 3 months
IGF-1 Age- and sex-specific laboratory range Safety check; a rise suggests a contaminant or stacked agent

Cadence: Baseline before starting; weight and waist every 2 weeks; fasting glucose, glycated hemoglobin and IGF-1 at 8–12 weeks and at the end of each course; body composition at the end of each 12-week course

Qualitative Assessment

  • Injection-site redness, swelling or pain
  • Headache or gastrointestinal upset
  • Energy and exercise tolerance
  • Joint pain and function, when used for osteoarthritis
  • Hunger and satiety, expected to stay unchanged